Publications by authors named "Gary Hamann"
Background: In the Systolic Heart failure treatment with the I inhibitor Trial (SHIFT) randomised placebo-controlled trial, ivabradine was shown to reduce hospital admissions for worsening heart failure (HF) and deaths due to HF in patients with symptomatic systolic HF and an elevated resting heart rate (HR). This analysis evaluates the cost effectiveness of adding ivabradine to optimal standard HF treatment in patients with a HR≥77 bpm.
Methods: A Markov model was developed to assess the impact of ivabradine on mean survival and quality of life over a patient's lifetime (10 years).